Drug makers Harness Experimental Biologics to Broaden Pipeline in Atopic Dermatitis Drugs Market, New Therapies to Help Market Clock CAGR of ~27% during 2019 - 2027:TMR

- Targeted approach of biologic drugs in  atopic dermatitis drugs market toward inflammatory responses to propel valuation of the segment to climb from ~US$ 15.3 billion in 2018 to ~US$ 15.3 billion by 2027

- Retail pharmacies to retain its popularity for end users, non-steroid-based option such as topical PDE4 inhibitor drugs to gain traction

ALBANY, N.Y., Sept. 14, 2020 /PRNewswire/ -- High prevalence and recurrence rate of moderate-to-severe atopic dermatitis, one of the most common chronic inflammation of the skin, has spurred research, paving the way to new therapies in atopic dermatitis drugs market.

High risk of recurrence in adults has nudged healthcare companies to take part in the development of novel therapies to overcome the side effects associated with traditional immunosuppressant medications. In this regard, experimental biologics are attracting sizable research interest.

The share of the biologic drug segment in the global atopic dermatitis drugs market is expected to rise from ~42% in 2018 to ~77% in 2027.

Overall, the global market is expected to expand at robust CAGR of 27% from 2019 to 2027. In 2018, its revenue was pegged at ~US$ 2.2 Bn.

Request for Analysis of COVID-19 Impact on Atopic Dermatitis Drugs Market – https://www.transparencymarketresearch.com/covid19.php

Key Findings of Atopic Dermatitis Drugs Market Report

• Retail pharmacies are one of the promising segments in the market based on distribution channel
• The segment to expand from ~US$ 1.3 Bn in 2018 to ~US$ 15.3 Bn by the end of 2027
• Of all the drug classes, biologics held the leading market share in 2018
• PDE4 inhibitors segment is the second-leading segment, and is expected to rise at promising growth rate during 2019 – 2027
• North America contributed the major share in 2018
• The aforementioned segment is trailed by Europe market
• The fastest growth rate during the forecast period is expected to come from Asia Pacific

Explore 145 pages of top-notch research, incisive insights, and detailed country-level projections on Atopic Dermatitis Drugs Market (Drug Class: Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027 at https://www.transparencymarketresearch.com/report-toc/73639

Atopic Dermatitis Drugs Market: Key Driving Factors and Promising Avenues

• Pressing need for the incidence and prevalence in atopic dermatitis is continuously expanding the pipeline in atopic dermatitis drugs market. Per a recent finding, 20% of children and 10% of adults in industrialized countries suffer from this chronic inflammatory skin disease
• According to a recent epidemiological data, the prevalence is 15–30% in both cohorts.
• Demand for novel, targeted therapies are attracting the interest of industry players, owing to the potential in increasing the effectiveness of severe atopic dermatitis treatments.
• The focus on new treatment pathways through experimental biologics is a prominent example of modern therapies.
• Increasing understanding of pathogenesis of the diseases has shifted the attention away from traditional immunosuppressant, opening new avenues in the atopic dermatitis drugs market.
• The prevalence of eczema is spurring developments in PDE4 inhibitors segment
• A multidimensional approach toward the development of pharmacological therapies is boosting new opportunities in the atopic dermatitis drugs market.
• Growing preference of biologic drugs is one of the key trends that have set the pace of innovation in drug pipelines.

Request Brochure of Atopic Dermatitis Drugs Market Report - https://www.transparencymarketresearch.com/brochure.php

Atopic Dermatitis Drugs Market: Regional Landscape

Regionally, rapidly increasing approvals and fast-paced commercialization of novel therapeutics are the key factors cementing the revenue potential of North America atopic dermatitis drugs market. The regional market is expected to see rapid penetration, with major share of opportunities to come from the U.S. and Canada.

On the other hand, Asia Pacific is expected to rise at remarkable pace during the forecast period. The growing number of new entrants and rise in research investments by established players in this region are boosting the growth. A large patient population has also kept the region increasing lucrative avenue for various drugs makers in the atopic dermatitis drugs market.

Purchase the Atopic Dermatitis Drugs Market Report - https://www.transparencymarketresearch.com/checkout.php

Atopic Dermatitis Drugs Market: Competitive Landscape

Numerous players in recent years have increased their stakes in biologics to gain a competitive edge. They are trying to get fast approvals by agencies such as the U.S. FDA. Most companies are expanding their understanding of the immune and inflammatory pathways underlying severe atopic dermatitis.

Some of the well-entrenched stakeholders in the atopic dermatitis drugs market are Teva Pharmaceutical Industries Ltd., Bausch Health, Novartis AG, Sanofi, and Pfizer, Inc.

Browse More Press Release - https://www.transparencymarketresearch.com/press-releases.htm

The Atopic Dermatitis Drugs market is segmented based on:

Drug Class

• Corticosteroids
• Calcineurin Inhibitors
• PDE4 Inhibitors
• Biologics

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region

• North America
• US
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• U.K.
• Rest of Europe
• Middle East and Africa
• GCC Countries
• South Africa
• Rest of Middle East & Africa
• Asia Pacific
• China
• Japan
• India
• Australia & New Zealand
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America

Explore Transparency Market Research's award-winning coverage of the global Healthcare Industry:

Venous Skin Ulcer Treatment Market: According to the report, the global venous skin ulcer treatment market was valued at US$ 2.6 Bn in 2019. It is expected to expand at a CAGR of ~5% during the forecast period from 2020 to 2030, the availability of different skin substitutes and rise in patient awareness and healthcare expenditure are major factors that propel the global market

Cosmetic Lasers Market: According to the report, the global cosmetic laser market was valued at US$ 1,455.1 Mn in 2017. It is anticipated to expand at a CAGR of 13.7% from 2018 to 2026, Expansion in the cosmetic industry and rise in awareness about physical appearance among individuals are likely to drive the market

Medical Aesthetic Devices Market: The global medical aesthetic devices market is likely to be driven by the increased adoption of minimally invasive procedures, awareness toward cosmetic procedures, and rising number of obese people in the world. In addition, technological progress in the medical field is likely to drive the demand for medical aesthetic procedures in the years to come

Browse Our Latest Reports - https://www.transparencymarketresearch.com/latest.htm

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision."

Browse More Upcoming Reports by Transparency Market Research: https://www.transparencymarketresearch.com/upcoming.htm

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Press Release Source: https://www.transparencymarketresearch.com/pressrelease/atopic-dermatitis-drugs-market.htm
Website: https://www.transparencymarketresearch.com/

Logo: https://mma.prnewswire.com/media/1085206/Transparency_Market_Research_Logo.jpg